Article thumbnail

Effect of Phosphodiesterase Inhibition on Insulin Resistance in Obese Individuals

By Jennifer E. Ho, Pankaj Arora, Geoffrey A. Walford, Anahita Ghorbani, Derek P. Guanaga, Bishnu P. Dhakal, Daniel I. Nathan, Emmanuel S. Buys, Jose C. Florez, Christopher Newton‐Cheh, Gregory D. Lewis and Thomas J. Wang

Abstract

Background: Obesity is associated with cardiometabolic disease, including insulin resistance (IR) and diabetes. Cyclic guanosine monophosphate (cGMP) signaling affects energy balance, IR, and glucose metabolism in experimental models. We sought to examine effects of phosphodiesterase‐5 inhibition with tadalafil on IR in a pilot study of obese nondiabetic individuals. Methods and Results: We conducted a randomized, double‐blinded, placebo‐controlled trial of adults age 18 to 50 years with obesity and elevated fasting insulin levels (≥10 μU/mL). Participants were randomized to tadalafil 20 mg daily or placebo for 3 months. Oral glucose tolerance tests were performed, and the effect of tadalafil on IR was examined. A total of 53 participants (mean age, 33 years; body mass index [BMI], 38 kg/m2) were analyzed, 25 randomized to tadalafil and 28 to placebo. In the overall sample, measures of IR did not differ between tadalafil and placebo groups at 3 months. However, in individuals with severe obesity (BMI ≥36.2 kg/m2), tadalafil use was associated with improved IR (homeostatic model assessment for IR), compared to placebo (P=0.02, respectively). Furthermore, one measure of β‐cell compensation for IR (oral disposition index) improved with tadalafil in the overall sample (P=0.009) and in the subgroup with severe obesity (P=0.01). Conclusion: Results of this pilot study did not show improvements in IR with tadalafil, compared to placebo. However, tadalafil may have favorable effects on β‐cell compensation, particularly in individuals with severe obesity. Future studies evaluating the potential metabolic benefits of cGMP modulation in obesity are warranted. Clinical Trial Registration URL: ClinicalTrials.gov. Unique Identifier: NCT01444651

Topics: Preventive Cardiology, cGMP, insulin resistance, obesity, phosphodiesterase type 5 inhibition
Publisher: 'Ovid Technologies (Wolters Kluwer Health)'
Year: 2015
DOI identifier: 10.1161/JAHA.114.001001.
OAI identifier: oai:dash.harvard.edu:1/14065535
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://nrs.harvard.edu/urn-3:H... (external link)
  • http://dx.doi.org/10.1161/JAHA... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.